Trial reportHaematologica2009
A phase II study of bortezomib in patients with MALT lymphoma.
Trial report in Haematologica, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 62 citations in OpenAlex.
- A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.British journal of haematology · 2015Trial
- Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.Haematologica · 2011Trial
- Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.American journal of hematology · 2010Trial
- Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.Current treatment options in oncology · 2025Review
- Genetic Characterization and Clinical Features ofCancers · 2021Article
- Article
- Marginal Zone Lymphoma: State-of-the-Art Treatment.Current treatment options in oncology · 2019Review
- Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas.Frontiers in oncology · 2019Review
- Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.Cancer management and research · 2018Review
- Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.The oncologist · 2015Review
- Radical surgery may be not an optimal treatment approach for pulmonary MALT lymphoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Molecular Pathogenesis of MALT Lymphoma.Gastroenterology research and practice · 2015Review
- Bortezomib for the treatment of non-Hodgkin's lymphoma.Expert opinion on pharmacotherapy · 2014Review
- Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas.World journal of gastroenterology · 2014Review
- Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type.Clinical journal of gastroenterology · 2013Article
- Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.Therapeutic advances in hematology · 2012Article
- Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.Haematologica · 2012Article
- Recent developments in nongastric mucosa-associated lymphoid tissue lymphoma.Current hematologic malignancy reports · 2011Review
- Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile.AAPS PharmSciTech · 2011Article
- Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.The Journal of biological chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have performed a phase II study to evaluate bortezomib in patients with MALT-lymphoma. Sixteen patients entered the trial, 4 had gastric MALT-lymphoma, 7 of the ocular adnexa, one of the colon, and 2 of the parotid, and one patient each the lung and the breast. Bortezomib was given at 1.5 mg/m(2) days 1, 4, 8 and 11; repeated every 21 days. The overall response rate was 80% (13/16); 7 patients achieved complete remission (43%), 6 partial response (37%) and 3 stable disease. After a median follow-up of 23 months (range; 8-26), all patients are alive and 4 have relapsed. Fifteen patients required dose reductions due to either neuropathy (7 patients) or diarrhea (8 patients). Bortezomib appears to be active in patients with MALT-lymphoma. However, an unexpectedly high rate of toxicities was seen, warranting assessment of combination schedules with bortezomib at a lower dose than given in our study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.